TY - JOUR
T1 - Lipidomic Profiling Identifies a Novel Lipid Signature Associated with Ethnicity-Specific Disparity of Bladder Cancer
AU - Reddy, Karthik Reddy Kami
AU - Piyarathna, Danthasinghe Waduge Badrajee
AU - Kamal, Abu Hena Mostafa
AU - Putluri, Vasanta
AU - Ravi, Shiva Shankar
AU - Bollag, Roni J.
AU - Terris, Martha K.
AU - Lotan, Yair
AU - Putluri, Nagireddy
N1 - Funding Information:
Funding: This research was fully supported by NIH/NCI R01CA220297 (N.P) and NIH/NCI R01CA216426 (N.P.), DOD W81XWH-21-1-0613 (CA200996) (N.P) and partially funded by NIH grant numbers, P42ES027725 (N.P), P30CA125123 Metabolomics Shared Resources (N.P.). It received support from UTSW Simmons Comprehensive Cancer Center’s Tissue Management Shared Resource and was supported by the National Cancer Institute of the National Institutes of Health under award number P30CA142543, P30ES030285. CPRIT RP210227 (N.P) to the Proteomics and Metabolomics Core Facility, Alkek Center for Molecular Discovery and Agilent Technologies Center for Excellence in Mass Spectrometry. This research was conducted in part in the Georgia Cancer Center Shared Resources.
Funding Information:
This research was fully supported by NIH/NCI R01CA220297 (N.P) and NIH/NCI R01CA216426 (N.P.), DOD W81XWH-21-1-0613 (CA200996) (N.P) and partially funded by NIH grant numbers, P42ES027725 (N.P), P30CA125123 Metabolomics Shared Resources (N.P.). It received support from UTSW Simmons Comprehensive Cancer Center’s Tissue Management Shared Resource and was supported by the National Cancer Institute of the National Institutes of Health under award number P30CA142543, P30ES030285. CPRIT RP210227 (N.P) to the Proteomics and Metabolomics Core Facility, Alkek Center for Molecular Discovery and Agilent Technologies Center for Excel-lence in Mass Spectrometry. This research was conducted in part in the Georgia Cancer Center Shared Resources.
Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/6
Y1 - 2022/6
N2 - Bladder Cancer (BLCA) is the ninth most frequently diagnosed cancer globally and the sixth most common cancer in the US. African Americans (AA) exhibit half the BLCA incidence compared to European Americans (EA), but they have a 70% higher risk of cancer-related death; unfortunately, this disparity in BLCA mortality remains poorly understood. In this study, we have used an ethnicity-balanced cohort for unbiased lipidomics profiling to study the changes in the lipid fingerprint for AA and EA BLCA tissues collected from similar geographical regions to determine a signature of ethnic-specific alterations. We identified 86 lipids significantly altered between self-reported AA and EA BLCA patients from Augusta University (AU) cohort. The majority of altered lipids belong to phosphatidylcholines (PCs), phosphatidylethanolamines (PEs), ly sophosphatidylcholines (lysoPCs), phosphatidylserines (PSs), and diglycerides (DGs). Interestingly, levels of four lysoPCs (lyso PCs 20:3, lyso PCs 22:1, lyso PCs 22:2, and lyso PCs 26:1) were elevated while, in contrast, the majority of the PCs were reduced in AA BLCA. Significant alterations in long-chain monounsaturated (MonoUN) and polyunsaturated (PolyUN) lipids were also observed between AA and EA BLCA tumor tissues. These first-in-field results implicate ethnic-specific lipid alterations in BLCA.
AB - Bladder Cancer (BLCA) is the ninth most frequently diagnosed cancer globally and the sixth most common cancer in the US. African Americans (AA) exhibit half the BLCA incidence compared to European Americans (EA), but they have a 70% higher risk of cancer-related death; unfortunately, this disparity in BLCA mortality remains poorly understood. In this study, we have used an ethnicity-balanced cohort for unbiased lipidomics profiling to study the changes in the lipid fingerprint for AA and EA BLCA tissues collected from similar geographical regions to determine a signature of ethnic-specific alterations. We identified 86 lipids significantly altered between self-reported AA and EA BLCA patients from Augusta University (AU) cohort. The majority of altered lipids belong to phosphatidylcholines (PCs), phosphatidylethanolamines (PEs), ly sophosphatidylcholines (lysoPCs), phosphatidylserines (PSs), and diglycerides (DGs). Interestingly, levels of four lysoPCs (lyso PCs 20:3, lyso PCs 22:1, lyso PCs 22:2, and lyso PCs 26:1) were elevated while, in contrast, the majority of the PCs were reduced in AA BLCA. Significant alterations in long-chain monounsaturated (MonoUN) and polyunsaturated (PolyUN) lipids were also observed between AA and EA BLCA tumor tissues. These first-in-field results implicate ethnic-specific lipid alterations in BLCA.
KW - bladder cancer
KW - ethnicity-specific disparity
KW - lipidomics
UR - http://www.scopus.com/inward/record.url?scp=85132592617&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85132592617&partnerID=8YFLogxK
U2 - 10.3390/metabo12060544
DO - 10.3390/metabo12060544
M3 - Article
C2 - 35736477
AN - SCOPUS:85132592617
SN - 2218-1989
VL - 12
JO - Metabolites
JF - Metabolites
IS - 6
M1 - 544
ER -